Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Sees Large Growth in Short Interest

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) saw a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 32,362 shares, a growth of 1,083.3% from the May 14th total of 2,735 shares. Approximately 5.9% of the shares of the stock are sold short. Based on an average daily volume of 54,195 shares, the short-interest ratio is presently 0.6 days.

Sigyn Therapeutics Price Performance

Shares of Sigyn Therapeutics stock remained flat at $0.04 during trading on Tuesday. 3,000 shares of the stock traded hands, compared to its average volume of 30,737. The stock’s 50-day simple moving average is $0.04 and its 200 day simple moving average is $0.62. The stock has a market cap of $100,330.00, a P/E ratio of -0.01 and a beta of -0.06. Sigyn Therapeutics has a 1-year low of $0.01 and a 1-year high of $5.00.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.